Gilead's Positive Phase II Data On Quad Pill For HIV Eases Analysts Concerns

With two novel components included in Gilead's investigational four-drug, fixed-dose combination pill for HIV, the company has a full clinical program ahead of it - but the first Phase II results offer early signs of promise